Literature DB >> 21079651

Role of NF-κB in the skeleton.

Deborah Veis Novack1.   

Abstract

Since the discovery that deletion of the NF-κB subunits p50 and p52 causes osteopetrosis in mice, there has been considerable interest in the role of NF-κB signaling in bone. NF-κB controls the differentiation or activity of the major skeletal cell types - osteoclasts, osteoblasts, osteocytes and chondrocytes. However, with five NF-κB subunits and two distinct activation pathways, not all NF-κB signals lead to the same physiologic responses. In this review, we will describe the roles of various NF-κB proteins in basal bone homeostasis and disease states, and explore how NF-κB inhibition might be utilized therapeutically.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21079651      PMCID: PMC3193402          DOI: 10.1038/cr.2010.159

Source DB:  PubMed          Journal:  Cell Res        ISSN: 1001-0602            Impact factor:   25.617


  99 in total

1.  Oscillating fluid flow activation of gap junction hemichannels induces ATP release from MLO-Y4 osteocytes.

Authors:  Damian C Genetos; Curtis J Kephart; Yue Zhang; Clare E Yellowley; Henry J Donahue
Journal:  J Cell Physiol       Date:  2007-07       Impact factor: 6.384

2.  Effect of blockade of TNF-alpha and interleukin-1 action on bone resorption in early postmenopausal women.

Authors:  Natthinee Charatcharoenwitthaya; Sundeep Khosla; Elizabeth J Atkinson; Louise K McCready; B Lawrence Riggs
Journal:  J Bone Miner Res       Date:  2007-05       Impact factor: 6.741

3.  TRAF6 ubiquitin ligase is essential for RANKL signaling and osteoclast differentiation.

Authors:  Betty Lamothe; William K Webster; Ambily Gopinathan; Arnaud Besse; Alejandro D Campos; Bryant G Darnay
Journal:  Biochem Biophys Res Commun       Date:  2007-06-11       Impact factor: 3.575

4.  NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1.

Authors:  Teruhito Yamashita; Zhenqiang Yao; Fang Li; Qian Zhang; I Raul Badell; Edward M Schwarz; Sunao Takeshita; Erwin F Wagner; Masaki Noda; Koichi Matsuo; Lianping Xing; Brendan F Boyce
Journal:  J Biol Chem       Date:  2007-05-07       Impact factor: 5.157

5.  A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands.

Authors:  Molly D Magnano; Eliza F Chakravarty; Corrie Broudy; Lorinda Chung; Ariella Kelman; Jennifer Hillygus; Mark C Genovese
Journal:  J Rheumatol       Date:  2007-05-15       Impact factor: 4.666

6.  Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction.

Authors:  Sawako Tatsumi; Kiyoaki Ishii; Norio Amizuka; Minqi Li; Toshihiro Kobayashi; Kenji Kohno; Masako Ito; Sunao Takeshita; Kyoji Ikeda
Journal:  Cell Metab       Date:  2007-06       Impact factor: 27.287

7.  Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

Authors:  Jonathan J Keats; Rafael Fonseca; Marta Chesi; Roelandt Schop; Angela Baker; Wee-Joo Chng; Scott Van Wier; Rodger Tiedemann; Chang-Xin Shi; Michael Sebag; Esteban Braggio; Travis Henry; Yuan-Xiao Zhu; Homer Fogle; Tammy Price-Troska; Gregory Ahmann; Catherine Mancini; Leslie A Brents; Shaji Kumar; Philip Greipp; Angela Dispenzieri; Barb Bryant; George Mulligan; Laurakay Bruhn; Michael Barrett; Riccardo Valdez; Jeff Trent; A Keith Stewart; John Carpten; P Leif Bergsagel
Journal:  Cancer Cell       Date:  2007-08       Impact factor: 31.743

8.  Bortezomib inhibits human osteoclastogenesis.

Authors:  I von Metzler; H Krebbel; M Hecht; R A Manz; C Fleissner; M Mieth; M Kaiser; C Jakob; J Sterz; L Kleeberg; U Heider; O Sezer
Journal:  Leukemia       Date:  2007-06-21       Impact factor: 11.528

9.  Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.

Authors:  Christina M Annunziata; R Eric Davis; Yulia Demchenko; William Bellamy; Ana Gabrea; Fenghuang Zhan; Georg Lenz; Ichiro Hanamura; George Wright; Wenming Xiao; Sandeep Dave; Elaine M Hurt; Bruce Tan; Hong Zhao; Owen Stephens; Madhumita Santra; David R Williams; Lenny Dang; Bart Barlogie; John D Shaughnessy; W Michael Kuehl; Louis M Staudt
Journal:  Cancer Cell       Date:  2007-08       Impact factor: 31.743

10.  Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth.

Authors:  Michel Jourdan; Jérôme Moreaux; John De Vos; Dirk Hose; Karène Mahtouk; Matthieu Abouladze; Nicolas Robert; Marion Baudard; Thierry Rème; Angela Romanelli; Hartmut Goldschmidt; Jean-François Rossi; Michel Dreano; Bernard Klein
Journal:  Br J Haematol       Date:  2007-06-03       Impact factor: 6.998

View more
  116 in total

Review 1.  NF-κB, the first quarter-century: remarkable progress and outstanding questions.

Authors:  Matthew S Hayden; Sankar Ghosh
Journal:  Genes Dev       Date:  2012-02-01       Impact factor: 11.361

2.  NF-κB Has a Direct Role in Inhibiting Bmp- and Wnt-Induced Matrix Protein Expression.

Authors:  Rohinton S Tarapore; Jason Lim; Chen Tian; Sandra Pacios; Wenmei Xiao; Daniel Reid; Hancheng Guan; Marcelo Mattos; Bo Yu; Cun-Yu Wang; Dana T Graves
Journal:  J Bone Miner Res       Date:  2015-08-06       Impact factor: 6.741

3.  Neonatal High Bone Mass With First Mutation of the NF-κB Complex: Heterozygous De Novo Missense (p.Asp512Ser) RELA (Rela/p65).

Authors:  Anja L Frederiksen; Martin J Larsen; Klaus Brusgaard; Deborah V Novack; Peter Juel Thiis Knudsen; Henrik Daa Schrøder; Weimin Qiu; Christina Eckhardt; William H McAlister; Moustapha Kassem; Steven Mumm; Morten Frost; Michael P Whyte
Journal:  J Bone Miner Res       Date:  2015-08-06       Impact factor: 6.741

4.  Andrographolide suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.

Authors:  Z J Zhai; H W Li; G W Liu; X H Qu; B Tian; W Yan; Z Lin; T T Tang; A Qin; K R Dai
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

Review 5.  Advances in osteoclast biology reveal potential new drug targets and new roles for osteoclasts.

Authors:  Brendan F Boyce
Journal:  J Bone Miner Res       Date:  2013-04       Impact factor: 6.741

6.  Sophocarpine attenuates wear particle-induced implant loosening by inhibiting osteoclastogenesis and bone resorption via suppression of the NF-κB signalling pathway in a rat model.

Authors:  Chen-He Zhou; Zhong-Li Shi; Jia-Hong Meng; Bin Hu; Chen-Chen Zhao; Yu-Te Yang; Wei Yu; Ze-Xin Chen; Boon Chin Heng; Virginia-Jeni Akila Parkman; Shuai Jiang; Han-Xiao Zhu; Hao-Bo Wu; Wei-Liang Shen; Shi-Gui Yan
Journal:  Br J Pharmacol       Date:  2018-02-14       Impact factor: 8.739

7.  Methionine down-regulates TLR4/MyD88/NF-κB signalling in osteoclast precursors to reduce bone loss during osteoporosis.

Authors:  V Vijayan; M Khandelwal; K Manglani; S Gupta; A Surolia
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

8.  The protective effect of lycopene intake on bone loss in ovariectomized rats.

Authors:  Yuki Iimura; Umon Agata; Satoko Takeda; Yuki Kobayashi; Shigeki Yoshida; Ikuko Ezawa; Naomi Omi
Journal:  J Bone Miner Metab       Date:  2014-07-05       Impact factor: 2.626

Review 9.  Inflammatory osteolysis: a conspiracy against bone.

Authors:  Gabriel Mbalaviele; Deborah V Novack; Georg Schett; Steven L Teitelbaum
Journal:  J Clin Invest       Date:  2017-06-01       Impact factor: 14.808

Review 10.  Osteoblast dysfunctions in bone diseases: from cellular and molecular mechanisms to therapeutic strategies.

Authors:  Pierre J Marie
Journal:  Cell Mol Life Sci       Date:  2014-12-09       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.